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INTRODUCTION 
The methylxanthines; caffeine, theophylline and theobromine have 
several pharmacological actions, of which, their ability to relax 
bronchial smooth muscle has great value in the treatment of chronic 
obstructive pulmonary disease. Theophylline is the most effective of 
the methylxanthines in this regard."'" Clinically, it is either used 
alone or in combination with beta-adrenergic agonists. The pharma-
cological basis of this combination depends on the ability of these 
two classes of drugs to increase the intracellular concentration of 
3', 5' cyclic-AMP. The methylxanthines, particularly theophylline, are 
competetive inhibitors of the enzyme phosphodiesterase. This enzyme 
catalyses the hydrolysis of cyclic-AMP to inactive 5'-AMP whereas the 
catecholamines increase the concentration of cyclic-AMP through sti-
mulation of adenyl cyclase, the enzyme responsible for cyclic-AMP 
synthesis from ATP. However, the therapeutic concentrations of 
theophylline achieved in vivo (50 um - 100 yM or 9-18 mcg/ml) inhibit 
1 2 
phosphodiesterase activity in many tissues by only 5-10%. ' Con-
sequently, to explain this disparity between in vivo and in vitro 
effects of similar concentrations, attention has been focused in re-
cent years on other potential mechanisms of action of methylxanthines. 
Animal studies with theophylline and caffeine have demonstrated a 
stimulatory effect of the xanthines on the adrenal medulla to cause a 
3 4 5 
release of catecholamines, specifically epinephrine. ' ' This adreno-
medullary release of catecholamines was noted to be independent of 
extracellular calcium concentrations and suggested that either theo-
phylline caused an intracellular translocation of calcium or induced the 
3 4 
release of catecholamines independently of calcium. ' This does not 
2 
apply to maximally achievable therapeutic concentrations of theophylline 
in vivo (50-100 yM) because the concentration of theophylline used in 
this study was 10-20 times greater than the therapeutic range of the 
drug. 
To explore the stimulating effect of the methylxanthines on the 
medulla, earlier studies in human subjects were performed by quantita-
tive determinations of norepinephrine (NE) and epinephrine (E) in the 
6 7 8 
urine following a caffeine or theophylline challenge. ' ' These 
studies showed a statistically significant increase in urinary concen-
trations of E and NE after the ingestion of the methylxanthine. Atuk 
et al^ demonstrated an increased excretion of urinary E (p <0.01) and 
NE (p <0.05) after a 500 mg infusion of aminophylline, which according 
to the author reflected an augmented concentration of the amines in the 
9 10 
plasma. Robertson et al ' reported that caffeine ingestion is one of 
the most potent stimuli for adrenomedullary catecholamine release. In-
gestion of 250 mg of caffeine by overnight-fasted supine subjects, re-
sulted in caffeine plasma concentrations averaging 10 mcg/ml and in-
creased E and NE concentrations by 207% and 75% respectively. The ef-
fect of theophylline on altering plasma catecholamines has not been 
evaluated in man. The availability of a sensitive single isotope 
radioenzymatic assay for plasma catecholamines has facilitated quanti-
11 12 13 
tative analysis of E and NE with great accuracy. ' ' This makes 
such a study a logical next step in the evaluation of alternative mecha-
nisms of action of theophylline. 
OBJECTIVES 
The objectives of this study were to evaluate whether theophylline 
causes a substantial increase of plasma E and NE and to justify this 
3 
elevation as an alternate mechanism of action for theophylline. Specifi-
cally, this study was designed to 1) quantify the release of plasma 
catecholamines after a theophylline challenge in normal subjects, 2) 
compare this rise in plasma catecholamines after theophylline or placebo 
administration and 3) document relationships between plasma theophyl-
line levels and plasma catecholamines. 
MATERIALS AND METHODS 
Subj ect Selection 
Five healthy, non-asthmatic, paid volunteers were selected for the 
study. There were two males and three females with an average age of 27 
(range 24-32) years. Health status and suitability to participate in the 
study were determined by a medical history and a physical examination 
conducted by a physician. Objective evaluation was completed by the 
following tests: serum electrolytes, blood urea nitrogen, serum glucose, 
complete blood count with differential, T^ and T^ and free thyroxine 
index and urinalysis. 
Exclusion Criteria 
The following exclusion criteria were used: 1) history of inges-
tion of coffee, tea, cola drinks and chocolate or any chocolate con-
taining candy bars three days prior to the study, 3) history of ciga-
rette smoking, 3) ingestion of alcoholic beverages during the three 
days prior to the study, 4) ingestion or inhalation of drugs or drug 
combination products containing a-methyldopa or isoproterenol since 
a-methyldopa metabolites and isoproterenol may interfere with the E 
assay, 5) history of ingesting any sympathomimetics, bronchodilators 
singularly or in combination, 6) history of ingesting any 
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antihypertensive, antidepressant or antiarrythmic medications, 7) use of 
diuretic agents, 8) use of sedative-hypnotics or any other psychoactive 
drugs, 9) exposure to any contrast media tests utilizing radioactive 
iodine, 10) history of hypertension, cardiovascular disease, asthma or 
lung disease, diabetes mellitus, hepatitis or unexplained jaundice, 
hypo and hyperthyroidism or seizure disorders. 
Study Design 
A double-blind, randomized, cross-over trial was conducted on two 
separate days at the University of Utah Hospital Clinical Research 
Center (CRC). There was a wash-out interval of three days between the 
two study days. On the first day, three subjects were randomly 
selected using a random number table, constructed by an independent 
observer, to receive the placebo and two subjects received theophylline. 
On the day of the study, each individual arrived at the CRC one 
hour before the placement of the intermittent infusion device (heparin 
lock) for venous blood sampling. The subjects provided a urine sample 
which was sent to the Clinical Toxicology Laboratory (CTL) of the Uni-
versity of Utah Hospital for qualitative analysis of methylxanthines. 
This was done to rule out any evidence of their ingestion. After 
voiding, the subjects remained supine in non-stimulating surroundings 
(a room with drapes drawn, no bright lights, minimal noise and no 
television). At the end of the first hour a #20 Angiocath® (Deseret 
Pharmaceuticals) was inserted to obtain blood samples. After the 
cannula was inserted the subjects remained recumbent for another hour 
to recover from any minor stress associated with the procedure. There-
after 5 ml of blood were drawn directly from the infusion set into an 
5 
evacuated tube containing an anticoagulant, 90 mg/ml of EGTA and 60 
® 
mg/ml of glutathione (Vacutainer Tube - Becton Dickinson). All blood 
samples were collected in these tubes. The tubes were gently inverted 
two-three times to mix the contents before placing them on ice. The 
first blood sample was analyzed for determination of baseline catechola-
mines, namely E, NE and dopamine (DA). Subsequently, a single dose of 
® 
5 mg/Kg of theophylline (Aminophyllin , Searle Laboratories) in a 
gelatin capsule was administered to the subjects who were to receive 
the drug. The AminophyllirT> tablets were crushed and placed in the 
capsule. Those receiving the placebo swallowed a lactose containing 
capsule which was indistinguishable from the theophylline capsule. 
Blood samples for theophylline and catecholamine determinations were 
obtained 1, 2 and 3 hours after ingestion of the theophylline or 
placebo capsule. Subjects receiving drug or placebo on the first day 
received the other preparation on the second day of the study. The 
time of the blood sample collection was consistent. The subjects 
assumed a recumbent position during the entire study, while vital 
signs (blood pressure, temperature, pulse and respiration) were moni-
tored hourly by the nursing staff. In addition, the subjects were 
monitored and observed for side-effects of theophylline, such as 
nausea, vomiting, restlessness, irritability, tachycardia and feelings 
of anxiety. The exact time of blood sampling was recorded by the 
nursing staff. The sample tubes were immediately placed in an ice bath 
and centrifuged within 15-20 minutes to separate the plasma from the 
® 
cells. The plasma was decanted into screw-capped glass tubes (Pyrex , 
#9826) and promptly frozen at -70°C to avoid the loss of catecholamines 
by oxidation. The samples were analyzed within three months of 
6 
collection by the radioenzymatic procedure described by Peuler and 
12 
Johnson. Frozen samples are stable for at least three months at 




The biochemical principle of the assay is based on the use of the 
enzyme catechol-O-methyltransferase (COMT) to transfer a radioactive 
methyl group from S-adenosyl-L-methionine (SAM) to an endogenous cate-
cholamine acceptor molecule to form a radioactive 0-methyl catechola-
12 3 mine derivative. Norepinephrine is converted to H-normetanephrine, 3 3 E to H-metanephrine and DA to H-3-methoxytyramine. The methyl donor 
SAM is converted to S-adenosyl-L-homocysteine (SAH). The biochemical 
materials kit to perform the plasma catecholamine assay was purchased 
® 
from Upjohn Diagnostics (Cat-A-Kit ). 
Plasma samples were thawed and any samples which were not clear 
were centrifuged to free the sample of fibrin and other particulate 
matter. Fifty yl aliquots of plasma without further extraction and de-
proteinization were added to an enzyme mixture containing buffer 
3 
solution, H-SAM (5 yCi per 10 yl) and COMT (rat liver enzyme). The 
total incubation volume was 100 yl. To an identical incubation mix-
ture containing a second 50 yl aliquot of the plasma sample was added 
10 yl of catecholamine standard solution (100 picogram each of NE, E and 
DA) as an internal standard. Blank tubes were also run containing the 
sample vehicle and each of the above reagents except plasma. The tubes 
were run in duplicate to ensure accuracy of the assay and the duplicate 
values were averaged for purposes of data analysis. 
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The mixture was incubated at 37°C for 60 minutes in a shaking water 
bath. The reaction was stopped using 50 yl of a solution consisting of 
a borate buffer (pH 11) and each of the products of the enzymatic 
reaction (normetanephrine, metanephrine and methoxytyramine) in a con-
centration of 4 mM, to serve as carriers for the radiolabeled products. 
3 
The resulting solution was mixed vigorously and the H-O-methylcatechol-
amines were extracted into 2 ml of toluene/isoamyl alcohol, 3:2 (v/v). 
At this and each subsequent step, the aqueous and organic phases were 
separated by centrifugation; the transfer of the organic phase was then 
facilitated by rapid freezing of the aqueous phase in an acetone/dry 
ice bath. The organic layer was decanted into a second tube containing 
3 
100 yl of 0.1 M acetic acid and the H-O-methylcatecholamines were 
partitioned with vigorous mixing into the aqueous layer. The toluene/ 
isoamyl layer was aspirated and discarded. The aqueous layer was then 
washed with 1 ml of toluene/isoamyl alcohol, 3:2 (v/v), and after 
centrifugation and freezing, the organic layer was discarded. For the 
differential determination of catecholamines, ethanol (100-150 yl) was 
added to the thawed acetic acid extract and vortexed until a clear solu-
tion resulted. Then 100 yl of the ethanol/acetic acid mixture was 
applied to a chromatography plate with a silica gel thin layer. Develop-
ment of the thin layer chromatography (TLC) plate was completed in a 
tertiary-amyl alcohol/toluene/40% methylamine solution, 6:2:3 (v/v/v). 
The solvent was permitted to migrate to three-quarters of the way to the 
top of the plate. The migration required 60-90 minutes. The plates were 
dried and three zones were visualized under ultraviolet light (UV). The 
top zone contained 3-methoxytyramine, the middle zone contained the 
8 
metanephrine and the bottom zone contained normetanephrine. The zones 
were marked on the plate, and the respective zones were scraped into 
their numbered scintillation vials for the differential assay. 
Dopamine Assay 
To the scintillation vials containing the top zone, 1 ml of 0.05 M 
ammonium hydroxide was added to elute the methoxytyramine from the 
silica gel. Ten ml of toluene/isoamyl alcohol/Liquiflor (700:300:50 
v/v/v) was then added to each vial and the vials were shaken vigorously. 
The vials were dark controlled (left at 4°C in the scintillation counter 
before counting) for one hour and then counted in a liquid scintillation 
counter (Packard, Model 3385). The radioactivity in the extract was 
proportional to the amount of dopamine in the sample being analyzed. 
Epinephrine Assay 
To the scintillation vials containing the middle zone, 1 ml of 0.05 
M ammonium hydroxide was added to elute the metanephrine from the silica 
3 3 gel. The H-metanephrine was then converted to H-vanillin with the 
addition of 50 yl of 4% w/v sodium metaperiodate solution followed by 
the addition of 50 yl of glycerol (10% v/v). The solution was then 
acidified with 1 ml of 0.1 M acetic acid followed by the addition of 10 
3 
ml of toluene/Liquiflor (1000/50 v/v). The H-vanillin produced by the 
periodate oxidation was then partitioned with vigorous shaking into the 
organic phase. The vials were dark controlled for one hour and the 




To the scintillation vials containing the bottom zone, 1 ml of 
0.05 M ammonium hydroxide was added to elute the normetanephrine from 
the silica gel and the rest of the assay was carried out identically to 
that described above for E. 
Radioactivity Counting and Calculations 
Control plasma samples provided by Upjohn Diagnostics (#876 HR) 
were simultaneously run to permit assessment of the performance of the 
kit and the assay technique. The linearity of the catecholamine assay 
up to 3,000 picograms/assay sample has been established with only a 
12 
slight decrease in radioactivity counting at the 10,000 pg level. 
The use of the internal standard, which is run in parallel with the 
samples, decreases any possible differences in the efficiency in the 
0-methylation and extraction efficiencies. The sensitivity of the assay 
ranges from 2-5 picograms for E and NE and 15-20 picograms for DA per 
50 yl of the sample. The average coefficient of variation is 3.2% for 
both E and NE and 4.0% for DA. 
It was not necessary to count separately instrument background 
since the background is a part of the assay blank and is therefore sub-
tracted in the mathematical calculations. Accurate counting was 
achieved by counting each vial for 5 minutes. The catecholamine con-
centration in picograms per ml was calculated according to the following 
equation: 
Catecholamine concentration (pg/ml): 
cpm sample or control-cpm blank x pg standard 
cpm(sample or control + standard)-cpm sample ml sample volume 
where cpm = counts per minute and all standards were 100 picograms. The 
sample volume used in all calculations was 0.05 ml. 
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Theophylline Assay 
The theophylline assay was performed by CTL. The assay method used 
was high pressure liquid chromatography (HPLC). The sensitivity of the 
assay was less than 1 mcg/ml and the coefficient of variation was less 
than 2%, the highest figure being 1.8% for a therapeutic range of 
theophylline of 4.9-15 mcg/ml. 
Urine Toxicology Screen 
The toxicology screen performed by CTL for the presence of methyl-
xanthines in the urine utilized thin layer chromatography and gas 
chromatography-mass spectrometry analysis. 
Statistical Analysis 
Data were analyzed by using a paired t-test for mean differences 
between catecholamine levels after theophylline and placebo administra-
tion and for estimating the significance of mean catecholamine differences 
over baseline. A Wilcoxon nonparametric test was also performed to 
eliminate the possibility of a non-normal distribution of data. In 
addition, the estimated power of the t-test (probability of rejecting 
the null hypothesis when it is indeed false) for rejecting NE elevation 
at three hours after theophylline administration, assuming a two-tailed 
alpha level of 0.05 was calculated. 
RESULTS 
After theophylline administration both E and NE were elevated at 
two and three hours, while DA levels displayed no significant consistent 
changes above baseline. 
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The plasma E, NE and DA levels in pg/ml after theophylline and 
placebo administration are depicted in Tables 1, 2 and 3 (Appendix A). 
Levels are reported as means of the duplicate values with the greatest 
variability between any two values not exceeding 25 pg/ml. The mean 
theophylline level in mcg/ml is also reported for all the five subjects 
at one, two and three hours after a single dose of 5 mg/Kg of theophyl-
line orally. All plasma theophylline levels on the days when subjects 
received the placebo capsule were reported as less than 2 mcg/ml, be-
cause quantitative determinations below this level were not detectable 
by the laboratory. 
Percentage changes from baseline (recorded as 0%) of plasma E at 
one, two and three hours after theophylline administration (Table 4, 
Appendix A) show maximum E levels at three hours post theophylline 
challenge for subjects 1, 2, 4 and 5, while subject 3 achieved the 
highest E level at two hours. Comparison of simultaneous, individual 
theophylline levels at one, two and three hours show subject 3 reaching 
a plasma theophylline peak at two hours, of 8 mcg/ml, which is consis-
tent with the E peak, while subjects 1, 2, 4 and 5 attained peak levels 
of 8, 8, 8 and 5 mcg/ml respectively at three hours. Table 4 depicts 
this pattern of rise and decline of plasma theophylline and E levels. 
The highest percentage increase of plasma E above baseline (287%), was 
observed in subject 3, with a concomitant theophylline level of 8 mcg/ml 
at two hours. Subjects 4 had a theophylline level of less than 2 mcg/ml 
at one and two hours post theophylline ingestion. The three hour level, 
however, was 8 mcg/ml. The percentage increases of plasma E in subject 
4 at one and two hours were 27.8% and 25.3% respectively; however, at 
three hours the E level increased 164% above baseline. Subject 5, on the 
12 
contrary, displayed a decrease in plasma E level at one and two hours 
following theophylline ingestion from baseline, with plasma theophylline 
levels of 4 and 5 mcg/ml respectively. At three hours, however, there 
was a 32% increase above baseline with a simultaneous theophylline level 
of 5 mcg/ml. The percentage changes in plasma E along with corresponding 
theophylline levels at one, two and three hours are depicted graphically 
in Figures la through 5a for subjects 1 through 5 (Appendix B). 
Percentage changes from baseline of plasma NE at one, two and three 
hours after theophylline administration (Table 5) show similar but less 
pronounced increases when compared to E above. Subjects 1, 2 and 4 ac-
hieved maximum NE increases at three hours and subject 3 attained peak 
9 
NE at two hours, with theophylline levels following the same pattern of 
rise. The highest percentage plasma NE increase of 97.6% above baseline, 
was observed in subject 1 with a simultaneous theophylline level of 8 
mcg/ml. Subject 5, again, consistently displayed a decrease in plasma 
NE below baseline. The graphical representations of NE percentage 
changes from baseline are depicted in Figure lb through 5b for patients 
1 through 5 (Appendix B). Figure 6 and 7 depict changes from baseline 
of plasma E and NE respectively in all five subjects after theophylline 
administration, with corresponding mean theophylline levels at one, two 
and three hours. 
Table 6 displays percentage changes from baseline of plasma DA after 
theophylline administration. Plasma DA determinations were performed 
only for some patients after placebo administration because of a lack of 
consistency of any significant changes after theophylline challenge. Con-
sequently, percentage change calculations and statistical analyses were 
not performed with the samples obtained following placebo administration. 
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Figure 8 graphically depicts the data recorded in Table 6. It is clear 
from the graph that no consistent changes are observed in plasma DA 
levels after theophylline ingestion. 
The mean catecholamine levels with placebo and theophylline adminis-
tration are represented in Table 7. A t-test for mean E and NE dif-
ferences over baseline after theophylline and placebo administration 
was performed using the data in Table 8 (Appendix A). Mean difference 
at three hours from baseline for E was 49.27 ± 9.62 (mean ± SD) pg/ml 
after theophylline administration; this was statistically significant 
at p <0.001. The mean difference at three hours from baseline for NE 
after theophylline administration was 128.27 ± 154.0 (mean ± SD) pg/ml, 
p = 0.136. The differences at one and two hours were not statistically 
significant and mean difference over baseline after placebo ingestion 
for all three catecholamines was also not significant. 
Using the data in Table 8 the E plasma level (difference from base-
line) at three hours after theophylline administration was significantly 
different from placebo (p = 0.01), while the NE plasma level at three 
hours was not significantly different from placebo (p = 0.149). The 
non-parametric test was in concordance with the t-test for differences. 
To rule out any ingestion of methylxanthines the urine toxicology 
screen was negative for all patients on both days of the study. There 
were no clinically significant changes observed in blood pressure, pulse 
and respiration in five subjects after theophylline or placebo on both 
days of the study. No untoward side effects were experienced after 
theophylline administration in any of the five subjects during the course 
of the study. 
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DISCUSSION 
This is the first double-blind, placebo-controlled, cross-over study-
reported in humans to test the hypothesis that theophylline can elevate 
circulating plasma catecholamines. This investigation has documented 
that theophylline administered as a single dose elevates the levels of 
plasma catecholamines, specifically E and NE. Previous studies have 
measured urinary concentrations of catecholamines after theophylline 
7 8 
stimulation, ' although the effect of a related xanthine, caffeine, on 
plasma catecholamine levels has recently been reported by Robertson 
, 10 et al. 
The methylxanthines, particularly theophylline, are competitive 
f 
inhibitors of the enzyme phosphodiesterase which catalyzes the conver-
sion of cyclic 3',5'-AMP to inactive 5'-AMP."'" The therapeutic concen-
trations of theophylline in the plasma are 10-20 yg/ml (50-100 uM), 
these in vivo concentrations do not effectively inhibit phosphodies-
2 
terase in vitro. This disparity between the in vivo and in vitro ef-
fects lends credence to the speculation that other mechanisms may be 
operative in this dosage range. 
To investigate the possibility of the adrenal glands playing a sig-
nificant role in mediating the bronchodilatory actions of theophylline, 
James''"'7 demonstrated that aminophylline (5 mg/Kg IV) reduced the broncho-
constriction induced by acetylcholine in guinea pigs within 30 seconds 
of administration. However, this response was markedly diminished after 
bilateral adrenalectomy was performed in the animals and after a beta-
16 
blocker (pronethalol) was given. Additionally, Strubelt reported that 
adrenal medullectomy combined with reserpine therapy completely 
abolished the theophylline and caffeine-induced rise in blood 
15 
glucose levels in anesthesized rats. He stated that this finding provides 
evidence that endogenous catecholamines are essentially implicated in the 
hyperglycemic actions of methylxanthines. Such experimental results 
imply that the release of catecholamines by methylxanthines is in part 
contributory to their pharmacologic actions. 
This study was performed to quantitate the rise of catecholamines 
in the plasma after theophylline administration. A single dose of 
theophylline (5 mg/Kg) caused a significant rise in the E level at three 
hours post ingestion, from a mean baseline of 56.52 pg/ml to a mean peak 
of 105.8 pg/ml. This represents a mean increase of 87% in E rise, while 
NE had a mean increase of 40% over baseline at three hours. Catechola-
mine levels obtained at one and two hours for both E and NE were not 
significant. This lack of significant elevations at one and two hours 
can possibly be explained on the following basis. Theophylline solutions 
or coated tablets in the absence of food achieve maximal concentrations 
within two hours, while food delays the rate but not the extent of drug 
absorption. Additionally, the small number of subjects in our study (5) 
and the large variability in plasma levels of NE and E may not allow 
for statistical significance at one and two hours. The power of the t-
test used (see statistical analysis) for five subjects was only 50%. Our 
subjects were not restricted from having meals before arriving at the 
CRC. Moreover, four of the five subjects achieved the highest theophyl-
line level three hours after the dose and there was a concomitant rise in 
the plasma catecholamines with theophylline elevation in the plasma. 
Therefore, mean levels of theophylline at one and two hours (4.4 and 5.6 
mcg/ml respectively) may have been insufficient to induce a significant 
increase of E and NE. Consequently, delayed absorption of theophylline 
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in the presence of food and failure to obtain serial blood determinations 
of catecholamines and theophylline beyond the three hour time, to ascer-
tain precisely the peak may explain the lack of more dramatic elevations 
of catecholamines as observed by Robertson et al."^ In their study, 
mean caffeine levels of 10 mcg/ml (range 4.2-26.0 mcg/ml) peaked at one 
hour after the ingestion of 250 mg of caffeine. In addition, the caffeine 
preparation was administered in a solution form, which has a more pre-
dictable and rapid rate of absorption."'" The above-mentioned caffeine 
levels attained in Robertson's study increased plasma NE levels by 75% 
and E by 207%. 
Four of the five subjects in this study displayed rising E and NE 
/ 
levels after theophylline challenge. The fifth subject was subjected to 
® 
multiple, traumatic placements of the Angiocath for blood sampling be-
cause of unsuccessful initial placement attempts. We believe that the 
elevated plasma E baseline level of 129.13 pg/ml may have masked any sub-
sequent increases at one, two and three hours. In addition, the plasma 
theophylline level at one, two and three hours for subject 5 was less than 
the theophylline level obtained in any of the other participants. 
In this study plasma E levels were significantly elevated more than 
NE levels after theophylline; this observation has also been made in 
previous studies measuring urinary and plasma concentrations of catechola-
mines after theophylline or caffeine administration. The catecholamine 
content of the adrenal medulla is largely E while NE constitutes about 20% 
of this total content.''" Norepinephrine is the transmitter of most sym-
pathetic postganglionic fibers and probably of certain tracts in the cen-
tral nervous system.^ Therefore, this relatively enhanced augmentation of 
E, compared to NE, can be explained on the basis of a predominant effect 
17 
of theophylline on the adrenomedullary system rather than a general sti-
mulation of the sympathetic nervous system. There were no consistent 
changes observed in plasma DA concentrations after theophylline challenge. 
Dopamine is the predominant neurotransmitter of the mammalian extra-
pyramidal system and the physiologic significance of plasma DA is not 
yet fully understood."'" Since we hypothesize that theophylline pri-
marily affects the adrenal medulla to cause catecholamine stimulation, 
it is not surprising that DA concentrations exhibited no consistent 
changes. 
No significant changes in blood pressure and heart rate after 
theophylline as compared to placebo administration were documented. 
t 
These observations are in conflict with the findings of Robertson et 
al"^ who demonstrated statistically significant increases in diastolic 
and systolic blood pressure after 250 mg of caffeine. These authors 
however, did not correlate this increase with caffeine or catecholamine 
levels in the plasma and it is unclear if all patients experienced 
this increase in blood pressure. Atuk et a.lJ  observed variable res-
ponses in blood pressure after a 500 mg aminophylline infusion but again 
no correlation with increased urinary catecholamine levels was described. 
A plausible explanation for a lack of a significant change in blood pres-
sure or heart rate in this study is the uniformly subtherapeutic plasma 
theophylline level of <10 mcg/ml obtained in our subjects. Clinically 
significant changes in heart rate and blood pressure have been observed 
with therapeutic concentrations of theophylline (10-20 mcg/ml) in non-




Theophylline is the most potent of the methylxanthines and is found 
to be effective in the management of the patients with chronic and re-
versible pulmonary disease."'" This study demonstrates that theophylline 
exercises a stimulatory effect to release catecholamines, specifically 
E. It is speculated that this effect is predominantly exerted on the 
adrenomedullary system. This augmentation of catecholamines in the 
plasma may contribute to the pharmacologic bronchodilatation observed 
with this agent, although this study was not designed to show such 
clinical significance. Such an increase of catecholamines in the plasma 
after theophylline administration also supports studies noting syner-
gistic interactions between theophylline and beta-agonists in patients 
18 19 with chronic obstructive pulmonary disease, although Wolfe et al 
failed to demonstrate such therapeutic and clinical synergism. 
In summary, this study was designed to observe any significant 
changes of catecholamine levels after the administration of a single dose 
n 
of theophylline in normal, non-asthmatic subjects. The study demon-
strated statistically significant increases in plasma E and NE, although 
E elevation was more pronounced. Plasma DA levels did not display any 
consistent changes. Further studies need to be performed to investigate 
the effect of chronic dosing on plasma catecholamine levels, specifically 
in asthmatic patients. The clinical significance of such an elevation 
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D P T 
X X 
0 0 
7.7 -3.5 5 









0 0 0 
63.4 40.2 5 





-15.9 13.9 7 








27.8 5.8 <2 







-23.2 12.4 4 
-12 7.1 5 
32 15.5 
D * = Percentage changes of E following administration of 5mg/kg of Theophylline 
p ** «. Percentage changes of E following placebo administration 
T *** » Theophylline level in mcg/ml 
+ » Baseline levels recorded as 0X and values at 1,2,3 hours are represented as percentage increases or decreases 
from baseline 
TABLE 












-25 3.5 5 
17.6 10.2 7 
97.6 13.0 8 
P 
X 
0 0 0 
45.8 2.8 5 
59.1 -25 7 






0 0 0 
-32.3 4.8 7 
36.2 -22 8 
26.6 -21 7 
D P T 
X X 
0 0 0 
-12.8 7.8 <2 
-9.2 12.4 <2 
75.5 18.8 8 
D P T 
X X 
0 0 0 
-33.7 21.9 4 
-31.1 8 5 
-27.1 2.8 5 
D * - Percentage changes of NE following administration of 5mg/Kg of Theophylline 
p *# = Percentage changes of NE following placebo administration 
T *** = Theophylline level in mcg/ml 
+ « Baseline levels recorded as 0X and values at 1,2,3 hours are represented as percentage increases or decreases 
from baseline 
TABLE 
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D * - Percentage changes of DA following administration of 5mg/Kg of Theophylline T ** = Theophylline level in mcg/ml 




MEAN CATECHOLAMINE LEVEL IN pg/ml 
EPINEPHRINE 
DRUG 
MEAN ± SD 
PLACEBO * 






MEAN ±. SD 
PLACEBO 







MEAN ± SD 
PLACEBO 




448.46±.l 17.13 248.06±78.51 
* The dopamine placebo determinations were not done for all the patients because of lacK of consistency 
of any change from baseline with theophylline administration. The 0.1,2 and 3 hour values are derived 
from means of 2,3,2 and 3 patients respectively. 
TABLE 













MEAN ±- SD 
EPINEPHRINE 
DRUG 











MEAN ± SD 
PLACEBO 





+ Calculations not done because of variable sample size 
* A tuo-tailed p value < .001 for mean difference at 3.0 hours 
from baseline after theophylline administration and a p value - .01 
for mean difference at 3.0 hours from baseline between drug and placebo 
** A two-tailed p value = .136 for mean difference at 3.0 hours 
from baseline after theophylline administration and a p value = .149 
for mean difference at 3.0 hours from baseline between drug and placebo 
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Figure 2a. Percentage changes from baseline of plasma epinephrine (E) in 
patient 2. 
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Figure 4a. Percentage changes from baseline of plasma epinephrine (E) in 
patient 4. 
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Percentage changes from baseline of plasma epinephrine (E) in 
patient 5. 
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Figure lb. Percentage changes from baseline of plasma norepinephrine (NE) 
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Figure b. Percentage changes from baseline of plasma norepinephrine (NE) 
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Figure 3b. Percentage changes from baseline of plasma norepinephrine (NE) 
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Figure b. Percentage changes from baseline of plasma norepinephrine (NE) 
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Figure 5b. Percentage changes from baseline of plasma norepinephrine (NE) 
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Percentage changes from baseline of plasma dopamine after 
theophylline administration in all 5 patients. 







We are conducting a study to determine whether theophylline, which 
is generally used in patients with asthma to relax their airways, has 
another mechanism of action for relaxation of the constricted airways. 
At present theophylline is thought to work on the smooth muscle cell 
of the bronchi by inhibiting an enzyme, thereby causing increased levels 
of a very important compound (c-AMP) necessary for relaxation to occur. 
Adrenaline, a substance that the body produces in response to stress 
and other stimuli, like coffee ingestion, also works on the smooth muscle 
of the airways to cause relaxation. It does this by increasing the 
levels of c-AMP, by another mechanism. As you may know, theophylline 
and adrenaline are sometimes used together to relieve the symptoms of 
an asthmatic patient. Theophylline has been known to cause the re-
lease of adrenaline in the body and we are trying to determine whether 
this increased level of adrenaline caused by theophylline can contribute 
to increased benefit from theophylline administration alone. 
The study will require you to come to the Clinical Research Center 
on two days. A heparin lock device to draw blood samples will be placed 
to measure adrenaline levels. The loss of blood will be minimal. Base-
line adrenaline levels and levels after theophylline administration in 
a capsule form, will be drawn. Side effects that may be experienced are 
increases in heart rate, nausea and a feeling of anxiety. 
In the event you sustain physical injury resulting from the research 
project in which you are participating, the University of Utah will pro-
vide you, without charge, emergency and temporary medical treatment not 
otherwise covered by insurance. Furthermore, if your injuries are caused 
by negligent acts or omissions of University employees acting in the course 
and scope of their employment, the University may be liable, subject to 
limitations prescribed by law, for additional medical costs and other 
damages you sustain. If you believe that you have suffered a physical 
injury as a result of participation in this research program, please con-
tact the Office of Research Administration, phone number 581-6903. 
Please read and sign the following statement: 
I have had the opportunity to ask questions about the study and I 
have received acceptable answers. I understand that I am free to with-
draw consent and to discontinue participation in the project or activity 
at any time without prejudice to the subject. 
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My professional goals after graduating from the Doctor of Pharmacy Program 
would include the following: 
1) Develop and participate in an Adult Inpatient Medicine service -
general medicine or specializing in a) Cardiology, b) Infectious 
Diseases, or c) Nephrology. 
2) Integrate patient service responsibilities with teaching respon-
sibilities towards undergraduate pharmacy students, staff pharma-
cists, Doctor of Pharmacy candidates and health related professionals. 
3) Involvement with clinical research. 
EDUCATIONAL BACKGROUND 
June 1981 Doctor of Pharmacy (Pharm.D.) 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Sept. 1976 - Bachelor of Science in Pharmacy 
June 1979 University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
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EDUCATIONAL BACKGROUND (Continued) 
Sept. 1975 -
June 1976 
Fulfilled partial degree requirements 
Master of Science in Nutrition 
University of Utah 
College of Health Sciences 
Salt Lake City, Utah 
July 1974 -
Jan. 1975 
Fulfilled partial degree requirements 
Master of Science in Foods and Nutrition 
Lady Irwin College 
University of Delhi, India 
July 1971 -
June 1974 
Bachelor of Science in Foods and Nutrition 
Lady Irwin College 
University of Delhi, India 
EDUCATIONAL EXPERIENCE 
Clinical Core Rotations: 
Adult Internal Medicine (12 weeks), University of Utah Hospital 
Pediatrics (6 weeks), Primary Children's Medical Center, SLC, Utah 
Surgery (6 weeks), University of Utah Hospital 
Drug Information (6 weeks), University of Utah Hospital 
Psychiatry (6 weeks), Veteran's Administration Hospital, SLC, Utah 
Ambulatory Care (6 weeks), University of Utah Hospital Clinic 
Veteran's Administration Hospital Geriatrics Units and 
Health Screening Center for Elderly, SLC, Utah 
Obstetrics and Gynecology (6 weeks), University of Utah Hospital 
and Utah State Division of Health 
Special Elective Rotations: 
Adult Internal Medicine (12 weeks), University of Utah Hospital 
and Holy Cross Hospital, SLC, Utah 
Pediatric Nephrology (6 weeks), University of Utah Hospital 
Primary Children's Medical Center and Dialysis Centre, SLC, Utah 
Pediatric Neurology (3 weeks), Primary Children's Medical Center, 
SLC, Utah 
Adult Oncology (3 weeks), University of Utah Hospital 
Adult Cardiology (6 weeks), LDS Hospital, SLC, Utah 
Infectious Diseases (6 weeks), University of Utah Hospital 
A Clinical Pharmacy Residency was not available at the University of 
Utah during my participation in the Doctor of Pharmacy Program, 
however, the above special elective clerkships meet the experience 
requirements of the newly implemented Clinical Pharmacy Residency 
Program at the University of Utah. 
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PROFESSIONAL EXPERIENCE 
June 1979-present Staff Pharmacist (Part-time) 
St. Marks Hospital 









St. Marks Hospital 




Grand Central Pharmacy 
Salt Lake City, Utah 
PROFESSIONAL ORGANIZATIONS 
American Society of Hospital Pharmacists 
Utah Society of Hospital Pharmacists 
American Pharmaceutical Association 
PROFESSIONAL ACTIVITIES AND AWARDS 
President, Rho Chi Honor Society (1978-1979) 
President, University Student's Union, Delhi University (1973-1974) 
Elected member of Student Advisory Committee (1980-1981) 
Volunteer, Hypertension Screening Clinic, University of Utah 
(1977-1979) 
Volunteer, Health Screening Center for Elderly (1980) 
Pharmacist, Yellowstone Lake Hospital, Yellowstone National Park 
(July 1980) 
Recipient of University Merit Scholarship Award, University of 
Utah (1977-1978) 
Recipient of University Merit Scholarship Award, University of 
Utah (1978-1979) 
Recipient of Best Speaker at Inter-College Debate Contest, 
University of Delhi, India (1973) 
Recipient of Highest Academic Achievement Award, University of 
Delhi, India (1972 and 1974) 
TEACHING FELLOWSHIPS 
Adult Internal Medicine - undergraduate clinical clerkship teaching 
responsibilities, Winter 1979 and Fall 1980 
Drug Information - Co-ordinating undergraduate course in Drug 
Information and writing Drug Reviews for University of Utah 
Formulary, Spring 1981 
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INVITED LECTURES AND PRESENTATIONS 
"Use of Benzodiazepines in the Elderly", presented to medical and 
nursing staff, Geriatrics Unit of Veteran's Administration Hospital. 
"Pharmacological Properties of Benzodiazepines", presented to nurs-
ing staff, Psychiatric Unit of Veteran's Administration Hospital. 
"Use of Tricyclic Antidepressants in Manic-Depressive Patients", 
presented to medical staff, Psychiatric Unit of Veteran's Adminis-
tration Hospital. 
"Oral Hypoglycemics in the Elderly", presented to nurses and other 
health professionals, Health Screening Center. 
"Medical Management of Hyperglycemic Hyperosmolar Non-Ketotic Coma", 
presented to medical staff, University of Utah Hospital. 
"Immunosuppressive Drug Regimens in Renal Allograft Recipients", 
presented to medical staff, University of Utah Hospital. 
"Pharmacokinetics of Theophylline", presented to medical staff, 
Primary Children's Hospital. 
"Drug Treatment of Malaria", presented to medical staff, University 
of Utah Hospital. 
"Drug Induced Hepatic Disease", presented to first-year Doctor of 
Pharmacy candidates taking Advanced Pharmacotherapeutics. 
"Use of Anti-infectives in Compromised Host", presented to under-
graduate pharmacy students taking "Anti-infectives" course. 
"Aminoglycosides in Anuric/Anephric Patients", to be presented to 
medical staff, University of Utah Hospital. 
"Use of Dilantin Saliva/Serum Levels", presented to medical staff, 
University of Utah Hospital. 
"Glomerulonephritis/Nephrotic Syndrome", to be presented to under-
graduate pharmacy students taking Pathophysiology. 
RESEARCH PROJECTS 
"Theophylline: An Alternative Proposed Mechanism of Action", 
Manju T Kumar, Martin D Higbee, Pharm.D., Stanley P Galant, M.D., 
funded by University of Utah Research Committee (1980-1981). 
Fulfills research requirements for the Doctor of Pharmacy Program. 
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RESEARCH PROJECTS (Continued) 
"Protein Enriched Formula Diets: A Comparative Nutritional Survey", 
Manju T Kumar, S Deshpande, Ph.D., Monica Gupta, M.S. (Nutrition). 
Fulfilled research requirements for the undergraduate Nutrition 
Degree (India, 1974). 
PUBLICATIONS 
"Minoxidil: A New Direct Acting Vasodilator for the Management of 
Hypertension", Manju T Kumar, Thomas Sudds, Pharm.D. Submitted to 
Western Journal of Medicine. 
